Topic List : Chronic Disease
Biomarker for lipedema discovered
Researchers have identified a molecule that ties lipedema to other lymphatic diseases, such as lymphedema, and distinguishes it from obesity.
New center for rare eye disease
A $10 million gift has enabled the launch of a center focusing on optic disc drusen, a poorly understood eye disease that can lead to visual impairment or even blindness.
Microbial loss, ulcerative colitis linked
Bacteria normally inhabiting healthy people’s intestines — and the anti-inflammatory metabolites these bacteria produce — are depleted in ulcerative colitis patients, a Stanford study shows.
Stanford-led teams nab top clinical research prizes
Winning studies were chosen by members of the Clinical Research Forum, a nonprofit foundation that promotes the understanding of clinical research and its impact on health and health care.
New incubator for life science innovation
A recently vacated building in Stanford Research Park will be the future home of a new life science incubator and lab suites. Located near campus, this incubator will serve as an anchor for a preeminent life science district.
Inflammation turns mutation deadly
A simple viral infection in the lungs of rats can become a lethal form of pulmonary hypertension if a common mutation is present, new Stanford research shows.
Success in rheumatoid arthritis trial
In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.
Possible drug target for cardiomyopathy
Stanford researchers have uncovered how a genetic mutation contributes to a heart disease known as familial dilated cardiomyopathy. Existing drugs correct the defect in heart cells grown in a petri dish, suggesting a new therapeutic target.
Chronic fatigue syndrome biomarker found
Stanford scientists devised a blood-based test that accurately identified people with chronic fatigue syndrome, a new study reports.
Drug reduces kidney failure in diabetics
Canagliflozin, a drug approved to lower glucose levels in diabetic patients, can slow the progression of kidney disease, according to a study co-authored by a Stanford Medicine researcher.